NPCE RNS System Explained: Growth Drivers and Setup for 2026

Core Insights - NeuroPace, Inc. (NPCE) is focused on growth through its RNS System, a brain-responsive implant aimed at reducing seizures in adults with drug-resistant focal epilepsy, with improved sales and margins expected in 2026 due to Medicare payment changes [2][11]. Product Overview - The RNS System is a closed-loop neuromodulation implant that monitors brain activity and delivers targeted stimulation to prevent seizures, with remote programming capabilities for clinicians [4][5]. - The system includes an implantable neurostimulator, tailored leads, and a patient remote monitor, along with a physician tablet and data management system [5]. Market and Demand - The primary market for the RNS System is adult patients with drug-resistant focal epilepsy, with an estimated U.S. addressable population of around 575,000 [8]. - Demand is driven by specialized epilepsy centers, with a reimbursement framework covering the implant procedure and ongoing monitoring, impacting over 200 million covered lives as of December 2024 [9]. Revenue Model - NeuroPace generates revenue from initial and replacement sales of the RNS System, linking growth to procedure volume and the installed base [7]. - The company reported $100 million in revenue for 2025, a 25% increase from 2024, with significant growth in prescribers and implanters [11][18]. Reimbursement Changes - Medicare reimbursement updates effective January 1, 2026, will increase physician payments for RNS procedures by approximately 43% and 45% for implants and replacements, respectively [12]. - Hospital reimbursement for RNS replacement procedures will rise to $31,526 from $21,444, enhancing the economic viability for hospitals and physicians [13]. Margin and Pricing Strategy - The company has maintained disciplined pricing strategies with low to mid-single-digit increases and improved manufacturing efficiencies, leading to a gross margin of 77.4% in Q4 2025 [15][16]. - For 2026, adjusted gross margin is projected to be between 81.5% and 82.5%, supported by ongoing pricing discipline and a cleaner revenue mix [17]. Future Outlook - For 2026, total revenue guidance is set at $98 million to $100 million, with RNS growth expected at 20% to 22%, excluding contributions from DIXI and idiopathic generalized epilepsy [20]. - The company anticipates typical seasonality in growth, with a projected revenue of $21 million to $22 million for Q1 2026 [21].